To what extent do the PANSS and CGI-S overlap?

被引:47
作者
Rabinowitz, Jonathan [1 ]
Mehnert, Angelika
Eerdekens, Marielle
机构
[1] Bar Ilan Univ, Ramat Gan, Israel
[2] Johnson & Johnson Pharmaceut Res & Dev, Beerse, Belgium
关键词
D O I
10.1097/01.jcp.0000218407.10362.6e
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: The Positive and Negative Symptom Scale (PANSS) and Clinical Global Impression (CGI-S) item for severity are used together to measure severity of psychotic illness. PANSS is the "gold standard" measure of efficacy, but it is not always feasible to use, yet the CGI-S requires validation. Objectives: To examine the overlap between PANSS and CGI-S. Methods: The overlap of the PANSS and CGI-S were examined using data from 7 large antipsychotic clinical trials (n = 4287). Results: Regression analysis identified 21% to 60% overlap of the measures depending on the trial and measurement point. The pooled study mean PANSS value corresponding with a CGI-S of 2, 3, and 4 were 67.1 (n = 799), 79.6 (n = 1645), and 92.4 (n = 1056), respectively. A decrease of I on the CGI-S corresponded to a 20% decline on the PANSS. Of the 37 planned comparisons in these studies, there was an agreement between the PANSS and CGI-S on change from baseline to end point on 32 comparisons and on dichotomized change variables (PANSS <=-20% and CGI-S <=-1 point) on 31 comparisons. The differences in the remaining comparisons would not have changed the conclusions of the studies. The positive and disorganized PANSS scales were the most closely related to the CGI-S, followed by hostility and negative scale with almost no association with anxiety/depression. Conclusions: The CGI-S and PANSS are correlated but are not synonymous. Both measures, however, show substantial agreement in detecting change, and the CGI-S shows overlap with the core symptoms of schizophrenia.
引用
收藏
页码:303 / 307
页数:5
相关论文
共 16 条
[1]  
[Anonymous], STAT POWER ANAL BEHA
[2]   Application of a new statistical approach to evaluate a clinical trial with panic disorder patients [J].
Bandelow, B ;
Brunner, E ;
Beinroth, D ;
Pralle, L ;
Broocks, A ;
Hajak, G ;
Rüther, E .
EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, 1999, 249 (01) :21-27
[3]   Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets [J].
Chue, P ;
Eerdekens, M ;
Augustyns, I ;
Lachaux, B ;
Molcan, P ;
Eriksson, L ;
Pretorius, H ;
David, AS .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 (01) :111-117
[4]  
DAHLKE F, 1992, PSYCHOPHARMACOL BULL, V28, P425
[5]   Treatment of schizophrenia with long-acting injectable risperidone: A 12-month open-label trial of the first long-acting second-generation antipsychotic [J].
Fleischhacker, WW ;
Eerdekens, M ;
Karcher, K ;
Remington, G ;
Llorca, PM ;
Chrzanowski, W ;
Martin, S ;
Gefvert, O .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (10) :1250-1257
[6]   Symptom correlates of global measures of severity in schizophrenia [J].
Goldman, M ;
DeQuardo, JR ;
Tandon, R ;
Taylor, SF ;
Jibson, M .
COMPREHENSIVE PSYCHIATRY, 1999, 40 (06) :458-461
[7]  
Guy W, 2000, HDB PSYCHIAT MEASURE, P100
[8]   Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotic [J].
Kane, JM ;
Eerdekens, M ;
Lindenmayer, JP ;
Keith, SJ ;
Lesem, M ;
Karcher, K .
AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (06) :1125-1132
[9]   Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis [J].
Khan, A ;
Brodhead, AE ;
Kolts, RL .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2004, 19 (03) :157-160
[10]   Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials [J].
Khan, A ;
Khan, SR ;
Shankles, EB ;
Polissar, NL .
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2002, 17 (06) :281-285